Impact of Sentinel Lymph Node Biopsy on Treatment Decision and Survival in Patients Aged ≥ 70 Years with Breast Cancer: A Retrospective Study

Chongshan Gu, MD1, Xue Chen, MD1, Lize Wang, MD1, Yingjian He, MD1, Tao Ouyang, MD1, Jinfeng Li, MD1, Tianfeng Wang, MD1, Tie Fan, MD1 and Zhaoqing Fan, MD1

Abstract

Background: Whether sentinel lymph node biopsy should be performed in patients ≥ 70 years old with early-stage invasive breast cancer is controversial. We examined the effect of sentinel lymph node biopsy on the treatment and outcomes in this population. Materials and Methods: In this retrospective study, patients aged ≥ 70 years who were treated for invasive breast cancer with sentinel lymph node biopsy followed by mastectomy or lumpectomy between 2010 and 2019 were identified from our database. Patients were compared according to sentinel lymph node status. Outcomes were analyzed using the Kaplan–Meier method and Cox multivariate analysis. Results: Of the 376 patients enrolled in this study, 311 (82.7%) were sentinel lymph node-negative and 65 (17.3%) were sentinel lymph node-positive. The median follow-up duration for all patients was 70 months. Systemic treatment and radiation were similar between sentinel lymph node-negative and -positive groups. Disease-free survival, distant disease-free survival, breast cancer-specific survival, overall survival were not significantly different between groups (88.2% vs 87.6%, 96.7% vs 94.8%, 96.2% vs 93.6%, and 93.5% vs 90.0%, respectively). Sentinel lymph node status, tumor size, chemotherapy, endocrine therapy, and adjuvant radiation were included in Cox multivariate analysis. None of the variables were found to significantly affect disease-free survival, distant disease-free survival, breast cancer-specific survival, and overall survival. Conclusions: Our analysis indicated that sentinel lymph node status may not affect systemic treatment decisions or survival in patients aged ≥ 70 years with breast cancer.

Keywords
breast cancer, sentinel lymph node biopsy, ≥ 70 years of age, treatment, survival

Abbreviations
ALND, axillary lymph node dissection; BCSS, breast cancer-specific survival; CI, confidence interval; DDFS, distant disease-free survival; DFS, disease-free survival; EUSOMA, European Society of Breast Cancer Specialists; HER2, human epidermal growth factor receptor 2; SIOG, International Society of Geriatric Oncology; SLN, sentinel lymph node; SLNB, sentinel lymph node biopsy; STROBE, Strengthening the Reporting of Observational Studies in Epidemiology; Sound, Sentinel Node vs Observation After Axillary Ultrasound; OS, overall survival.

Introduction

In the past 20 years, axillary staging for breast cancer has been a standard part of initial surgical treatment. Sentinel lymph node biopsy (SLNB) has become the standard of care for axillary staging over the past decade. Currently, the Choosing Wisely statement by the Society of Surgical Oncology, Ontario Health (Cancer Care Ontario) and ASCO guideline recommend against the routine use of sentinel node biopsy in clinically
Committee of the Beijing Cancer Hospital (2022YJZ30) on research protocol was examined and approved by the Ethics Committee of the Beijing Cancer Hospital (2022YJZ30) on April 18, 2022.

Materials and Methods

This study conforms to the STROBE guidelines. The research protocol was examined and approved by the Ethics Committee of the Beijing Cancer Hospital (2022YJZ30) on April 18, 2022.

Patient Characteristics

Data from patients ≥70 years old with primary breast cancer between 2010 and 2019 were retrospectively obtained from the database of Peking University Cancer Hospital. The inclusion criteria for this study were as follows: patients aged ≥70 years with newly diagnosed unilateral invasive breast cancers, with clinically negative nodes, who were treated with SLNB followed by mastectomy or lumpectomy. Patients with previous breast cancer or other cancers, bilateral breast cancers, or newly diagnosed breast carcinoma in situ were excluded. A total of consecutive 399 patients were initially included in this study. The overall success rate for SLN localization was 94.2% (376 / 399). Because SLN mapping was unsuccessful, 23 patients were not included in the final analysis. The need for specified informed consent was waived owing to the retrospective nature of the study. All patient details have been de-identified.

Sentinel Lymph Node Biopsy

Axillary lymph nodes were evaluated using ultrasound combined with fine-needle aspiration. Clinically negative nodes were defined as normal nodes under ultrasound or abnormal nodes that were confirmed negative by fine-needle aspiration. For SLNB, 99mTc-rituximab was used as the single tracer. Two of the three sites were chosen for tracer injection: the peritumoral breast parenchyma, subcutaneous, and subareolar tissues. SLNB was performed under local anesthesia. The samples were formalin-fixed and embedded in paraffin, with at least one cut in 5-mm intervals, and stained with hematoxylin and eosin. Cytokeratin immunohistochemistry was routinely performed. Isolated tumor cells in SLNs were defined as negative nodes. Macrometastatic and micrometastatic lesions were considered pathologically positive.

Follow-Up and Outcomes

The duration of follow-up was calculated from the date of surgery. The endpoints of this study were disease-free survival (DFS), distant disease-free survival (DDFS), breast cancer-specific survival (BCSS), and overall survival (OS). DFS events included local recurrence, regional recurrence, distant metastasis, contralateral breast cancer, non-breast secondary primary cancer, and any death. DDFS was measured from surgery until distant metastases were observed. BCSS was defined as the time to breast cancer-related death with patients censored at the date of the last follow-up or death from other causes. OS was defined as the time to any death.

Statistical Analysis

Statistical power calculations were not performed before the study. Patient characteristics were compared between subtypes using Pearson’s chi-square test and Fisher’s exact test. Survival probabilities were estimated using the Kaplan–Meier method. Cox proportional hazards regression was performed to assess the independent associations of several variables with DFS, DDFS, BCSS, and OS. Hazard ratios and their 95% confidence intervals (CIs) were estimated using a Cox model with a backward stepwise method. All reported p-values were two-sided with a value of <0.05 considered as statistically significant. All statistical analyses were performed using SPSS 23.0 (IBM, Armonk, NY, USA).

Results

A total of 376 patients ≥70 years old who underwent SLNB were included in our study (Figure 1): of these patients, 311 (82.7%) had a negative SLN and 65 (17.3%) had at least one positive node.

Table 1 shows the clinicopathological characteristics of patients stratified according to SLN status. One hundred and eighteen patients received adjuvant radiation therapy: 6/207 (2.9%) mastectomy patients underwent postmastectomy radiation therapy and 112/169 (66.3%) lumpectomy patients received whole breast (86/112, 76.8%) or intraoperative breast (26/112, 23.2%) radiation. A total of 321/324 (99.1%) patients who were estrogen receptor-positive and/or progesterone receptor-positive (>1% positive cells by immunohistochemistry staining) received endocrine treatment. Only 9/44 (20.5%) patients with HER2-positive tumors received trastuzumab.

The median age at diagnosis was 74 and 73 years in the SLN-negative and SLN-positive groups, respectively. SLN-positive patients were more likely to undergo axillary lymph node dissection (ALND) (P < 0.0001) and had larger tumors (P < 0.0001) compared to SLN-negative patients. Estrogen receptor, progesterone receptor, ki67, and HER2 status were not significantly different between groups. In terms of treatment, there were no statistically significant differences in surgery type, adjuvant radiation, chemotherapy, or endocrine treatment between the two groups (Table 1).
After a median follow-up of 70 (range 3–143) months, 30 (8.0%) patients experienced recurrence. Twenty-four SLN-negative patients experienced locoregional ($n = 6$) or distant ($n = 11$) recurrence, contralateral breast tumor ($n = 1$), or other primary cancers ($n = 6$). Six SLN-positive patients experienced locoregional ($n = 1$) or distant recurrence ($n = 4$) or other primary cancers ($n = 1$) (Table 2). The 5-year DFS rates were 88.2% (95% CI, 84.3–92.1%) in the SLN-negative group and 87.6% (95% CI, 79.8–95.4%) in the SLN-positive group. The 5-year DDFS was 96.7% (95% CI, 94.3–99.1%) in the SLN-negative group and 94.8% (95% CI, 88.9–99.9%) in the SLN-positive group. The 5-year BCSS was 96.2% (95% CI, 93.8–98.6%) in the SLN-negative group and 93.6% (95% CI, 86.6–99.9%) in the SLN-positive group. The 5-year OS was 93.5% (95% CI, 90.6–96.4%) in the SLN-negative group and 90.0% (95% CI, 81.6–98.4%) in the SLN-positive group. Kaplan–Meier survival analyses showed no significant differences in DFS, DDFS, BCSS, or OS between the two groups (Table 3). The variables of SLN status, tumor size, chemotherapy, endocrine therapy, and adjuvant radiation were included in the Cox multivariate analysis. None of the variables were found to significantly affect DFS, DDFS, BCSS, or OS. Multivariable analysis showed that SLN positivity was not significantly associated with DFS, DDFS, BCSS, or OS (Table 4).

**Discussion**

Our study found that the treatment of patients ≥70 years old was similar between the SLN-negative and SLN-positive groups. SLN status affected ALND but not the use of radiation, endocrine, or chemotherapy. There were no significant differences in DFS, DDFS, BCSS, or OS according to SLN status. The results of our study support the recommendation of omitting SLNB in patients ≥70 years old with early-stage invasive breast cancer.

The positive rate of SLNB in our study was 17.3%. It was lower than the positive rate of 25.6% in the entire population who underwent SLNB in our center, which was reported in another study. Meanwhile, only 6.2% of patients in the SLN-positive group had ≥4 lymph node metastases. Our data showed that elderly patients had a low tumor burden in the axillary lymph nodes, regardless of the positivity rate of SLNB or N2 stage. The indolent biological characteristics of tumors in elderly patients have also been reported by other studies.

In our study, 66.3% of lumpectomy patients received radiation and 20.5% of patients with HER2-positive tumor received trastuzumab. These data suggest that elderly patients are often treated with de-escalating adjuvant therapy. First, competing comorbid conditions, limited life expectancy, and concerns regarding the quality of life after treatment are important factors when making decisions about treatment plans for elderly patients. Second, adjuvant radiation therapy has not been proven to improve survival in this patient population. Furthermore, a retrospective study involving 492 patients showed that elderly patients with positive nodes were significantly less likely to receive chemotherapy than younger patients. Adjuvant treatment recommendations are increasingly based on biology rather than prognostic information coming from nodal statuses, such as triple-negative and HER2-positive breast cancer.

There is an ongoing debate regarding whether SLNB should be performed in patients ≥70 years old with early-stage invasive breast cancer. On one hand, two prospective studies and
Characteristics of Patients and SLNB Results.

| Variable                  | Negative SLN n = 311 | Positive SLN n = 65 | P Value |
|---------------------------|-----------------------|---------------------|---------|
| Age median (years)        | 74 (70–87)            | 73 (70–84)          | 0.238   |
| Surgery type              |                       |                     | 0.088   |
| Mastectomy                | 165 (53.1%)           | 42 (65.2%)          |         |
| Lumpectomy                | 146 (46.9%)           | 23 (34.8%)          |         |
| Histology                 |                       |                     | 0.108   |
| IDC                       | 240 (77.2%)           | 56 (86.2%)          |         |
| Other                     | 71 (22.8%)            | 9 (13.8%)           |         |
| Tumor size (cm)           |                       |                     | <0.0001 |
| ≤2 cm                     | 202 (65.0%)           | 27 (41.5%)          |         |
| >2 cm                     | 109 (35.0%)           | 38 (58.5%)          |         |
| N stage                   |                       |                     | <0.0001 |
| N0                        | 311 (100.0%)          | 0                   |         |
| N1                        | 0                     | 61 (93.8%)          |         |
| N2                        | 0                     | 4 (6.2%)            |         |
| Estrogen receptor         |                       |                     | 0.528   |
| Negative                  | 53 (17.0%)            | 9 (13.8%)           |         |
| Positive                  | 258 (83.0%)           | 56 (86.2%)          |         |
| Progesterone receptor     |                       |                     | 0.628   |
| Negative                  | 68 (21.9%)            | 16 (24.6%)          |         |
| Positive                  | 243 (78.1%)           | 49 (75.4%)          |         |
| Her2                      |                       |                     | 0.569   |
| Negative                  | 260 (83.6%)           | 51 (78.5%)          |         |
| Positive                  | 34 (10.9%)            | 10 (15.4%)          |         |
| Unknown                   | 17 (5.5%)             | 4 (6.2%)            |         |
| Ki67                      |                       |                     | 0.966   |
| <30%                      | 240 (77.2%)           | 50 (76.9%)          |         |
| ≥30%                      | 71 (22.8%)            | 15 (23.1%)          |         |
| No. of SLNs removed       |                       |                     | 0.010   |
| median                    | 2 (1–8)               | 3 (1–9)             |         |
| No. of positive SLNs      |                       |                     | <0.0001 |
| median                    | 0 (0–0)               | 1 (1–5)             |         |
| Axillary lymph node       |                       |                     |         |
| dissection                |                       |                     | <0.0001 |
| Yes                       | 3 (1.0%)              | 44 (67.7%)          |         |
| No                        | 308 (99.0%)           | 21 (32.3%)          |         |
| Adjuvant radiation        |                       |                     | 0.176   |
| Yes                       | 93 (29.9%)            | 25 (38.5%)          |         |
| No                        | 218 (70.1%)           | 40 (61.5%)          |         |
| Chemotherapy              |                       |                     | 0.574   |
| Yes                       | 31 (10.0%)            | 8 (12.3%)           |         |
| No                        | 280 (90.0%)           | 57 (87.7%)          |         |
| Endocrine therapy         |                       |                     | 0.561   |
| Yes                       | 264 (84.9%)           | 57 (87.7%)          |         |
| No                        | 47 (15.1%)            | 8 (12.3%)           |         |
| Trastuzumab               |                       |                     | 0.657   |
| Yes                       | 7 (2.3%)              | 2 (3.1%)            |         |
| No                        | 304 (97.7%)           | 63 (96.9%)          |         |

Abbreviations: IDC, invasive ductal carcinoma; SLN, sentinel lymph node.

One meta-analysis found that omission of axillary staging by ALND in women ≥70 years, with clinically negative axilla, resulted in an increased risk of regional recurrence, but did not affect overall and breast cancer-specific mortality. A recent study from the European Institute of Oncology using a matched analysis based on 1748 patients ≥70 years old found that axillary staging in elderly women did not impact long-term survival. Based on these evidence, the Choosing Wisely statement by the Society of Surgical Oncology, Ontario Health (Cancer Care Ontario) and ASCO guideline recommend that SLNB is not required for patients aged ≥70 years with clinically node-negative (T1N0) early-stage invasive breast cancer, which is hormone receptor-positive and HER2-negative. On the other hand, no solid evidence is available at this time for staging by SLNB compared with observation, but some retrospective studies concluded that SLNB may still provide important information affecting treatment and survival. The 2021 St Gallen consensus, European Society of Breast Cancer Specialists (EUSOMA), and International Society of Geriatric Oncology (SIOG) still recommend that patients aged ≥70 years should be offered the same surgery as younger patients. Currently, there are three ongoing trials focused on the comparison between SLNB and observation. One trial is examining the outcomes of lumpectomy without sentinel node biopsy in women aged ≥65 years with clinically node-negative breast cancer (NCT02564848). Another trial in the Netherlands is determining whether omitting the SLN procedure is not inferior to the current axillary staging regimen in clinically node-negative breast cancer patients undergoing breast-conserving therapy in terms of regional recurrence rate (NCT02271828). The SOUND trial is comparing SLNB with no surgery at all in the axilla when axilla ultrasonography findings are negative (NCT02167490).
Our study has several limitations. First, this study was retrospective in design, and power calculations were not conducted to estimate the required sample size. Second, studies with small sample populations are usually too underpowered to show any statistical significance. Third, selection bias was unavoidable due to the retrospective nature of the study.

Conclusions

In our study, SLN status may not affect systemic treatment decisions or survival in patients aged ≥70 years with breast cancer. Our results support the omission of SLNB in patients ≥70 years with clinically negative axillary lymph nodes. Several ongoing prospective trials will provide more evidence on this issue.

Acknowledgements

The authors acknowledge Xue Chen, who managed the database. We appreciate Yingjian He, who worked on the statistics.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by capital’s funds for health improvement and research (grant number 2018-2-2152).

Ethical Approval

The research protocol was examined and approved by the Ethics Committee of Beijing Cancer Hospital (2022YJZ30) on April 18, 2022.

ORCID iD

Chongshan Gu https://orcid.org/0000-0002-4071-6463

Supplemental Material

Supplemental material for this article is available online.

References

1. Choosing Wisely: Society of Surgical Oncology. http://www.choosingwisely.org/clinician-lists/sso-sentinel-node-biopsy-in-node-negative-women-70-and-over/

2. Brackstone M, Baldassarre FG, Perera FE, et al. Management of the axilla in early-stage breast cancer: Ontario Health (cancer care ontario) and ASCO guideline. J Clin Oncol. 2021;39(27):3056-3082.

3. Burstein HJ, Curigliano G, Thürlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer. 2021. Ann Oncol. 2021;32(10):1216-1235.

4. Biganzoli L, Battisti NML, Wildiers H, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22(7):e327-e340.

5. Von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577.

6. Chen X, He Y, Wang J, et al. Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients. Cancer Med. 2018;7(7):3066-3072.

7. Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor
characteristics, treatment choices, and survival. *J Clin Oncol.* 2010;28(12):2038-2045.

8. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. *J Clin Oncol.* 2013;31(19):2382-2387.

9. Grumpelt AM, Ignatov A, Tchaikovski SN, Burger E, Costa SD, Eggemann H. Tumor characteristics and therapy of elderly patients with breast cancer. *J Cancer Res Clin Oncol.* 2016;142(5):1109-1116.

10. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. *Lancet Oncol.* 2015;16(3):266-273.

11. Blackhall V, Bugelli M, Abbott N, Mullen R. The role of sentinel lymph node biopsy in planning adjuvant therapy for elderly women with low-risk breast cancer. *Breast J.* 2020;26(4):716-720.

12. Gentilini O, Veronesi U. Staging the axilla in early breast cancer: will imaging replace surgery? *JAMA Oncol.* 2015;1(8):1031-1032.

13. Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. *Ann Surg.* 2012;256(6):920-924.

14. Rudenstam CM, Zahrieh D, Forbes JF, et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. *J Clin Oncol.* 2006;24(3):337-344.

15. Liang S, Hallett J, Simpson JS, et al. Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: a systematic review and meta-analysis. *J Geriatr Oncol.* 2017;8(2):140-147.

16. Corso G, Magnoni F, Montagna G, et al. Long-term outcome and axillary recurrence in elderly women (≥70 years) with breast cancer: 10-years follow-up from a matched cohort study. *Eur J Surg Oncol.* 2021;47(7):1593-1600.

17. Xu L, Wen N, Qiu J, et al. Predicting survival benefit of sparing sentinel lymph node biopsy in low-risk elderly patients with early breast cancer: a population-based analysis. *Front Oncol.* 2020;11(10):1718.

18. Sun J, Mathias BJ, Sun W, et al. Is it wise to omit sentinel node biopsy in elderly patients with breast cancer? *Ann Surg Oncol.* 2021;28(1):320-329.